Glucose Metabolism Modification Induced by Radioligand Therapy with [(177)Lu]Lu/[(90)Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial

[(18)F]F-FDG (FDG) PET is emerging as a relevant diagnostic and prognostic tool in neuroendocrine neoplasms (NENs), as a simultaneous decrease in [(68)Ga]Ga-DOTA peptides and increase in FDG uptake (the “flip-flop” phenomenon) occurs during the natural history of these tumors. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Urso, Luca, Panareo, Stefano, Castello, Angelo, Ambrosio, Maria Rosaria, Zatelli, Maria Chiara, Caracciolo, Matteo, Tonini, Eugenia, Valpiani, Giorgia, Boschi, Alessandra, Uccelli, Licia, Cittanti, Corrado, Bartolomei, Mirco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612170/
https://www.ncbi.nlm.nih.gov/pubmed/36297443
http://dx.doi.org/10.3390/pharmaceutics14102009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612170/
https://www.ncbi.nlm.nih.gov/pubmed/36297443
http://dx.doi.org/10.3390/pharmaceutics14102009

Ejemplares similares